*	OR T5 T6
R1	Has_multiplier Arg1:T5 Arg2:T8	
R2	Has_value Arg1:T3 Arg2:T4	
*	OR T1 T2
R3	Has_value Arg1:T11 Arg2:T12	
*	OR T14 T15
R4	Has_multiplier Arg1:T14 Arg2:T13	
R5	Has_temporal Arg1:T17 Arg2:T18	
*	OR T21 T22
R6	Has_qualifier Arg1:T21 Arg2:T20	
R7	Has_qualifier Arg1:T22 Arg2:T20	
R8	causal Arg1:T23 Arg2:T21	
R9	causal Arg1:T23 Arg2:T22	
R10	Has_qualifier Arg1:T21 Arg2:T19	
R11	Has_qualifier Arg1:T22 Arg2:T19	
*	OR T26 T27
R12	Has_value Arg1:T26 Arg2:T25	
R13	AND Arg1:T24 Arg2:T26	
R14	Subsumes Arg1:T23 Arg2:T24	
R15	AND Arg1:T23 Arg2:T29	
R16	AND Arg1:T23 Arg2:T30	
R17	Has_value Arg1:T33 Arg2:T34	
R18	multi Arg1:T40 Arg2:T41	
R19	Has_qualifier Arg1:T36 Arg2:T40	
R20	Has_qualifier Arg1:T36 Arg2:T37	
R21	Has_qualifier Arg1:T36 Arg2:T38	
R22	Has_temporal Arg1:T43 Arg2:T39	
R23	multi Arg1:T42 Arg2:T43	
R24	Has_qualifier Arg1:T36 Arg2:T42	
R25	AND Arg1:T46 Arg2:T44	
R26	Has_mood Arg1:T46 Arg2:T45	
R27	AND Arg1:T47 Arg2:T48	
R28	Has_negation Arg1:T47 Arg2:T49	
R29	AND Arg1:T46 Arg2:T47	
R30	Has_value Arg1:T52 Arg2:T53	
R31	Has_value Arg1:T50 Arg2:T51	
R32	Has_value Arg1:T54 Arg2:T57	
R33	Has_value Arg1:T59 Arg2:T60	
*	OR T61 T62
R34	Has_value Arg1:T62 Arg2:T63	
R35	Has_value Arg1:T61 Arg2:T63	
R36	Subsumes Arg1:T64 Arg2:T66	
R37	Has_value Arg1:T64 Arg2:T65	
R38	AND Arg1:T67 Arg2:T64	
R39	Has_value Arg1:T55 Arg2:T57	
R40	Has_value Arg1:T56 Arg2:T57	
R41	AND Arg1:T68 Arg2:T64	
T1	Person 3 8	Males
T2	Person 13 20	females
T3	Person 21 24	age
T4	Value 25 34	≥18 years
T5	Condition 45 52	relapse
T6	Condition 56 66	refractory
T8	Multiplier 38 44	second
T9	Person 72 77	Males
T10	Person 82 89	females
T11	Person 90 93	age
T12	Value 94 103	≥60 years
T13	Multiplier 107 112	first
T14	Condition 113 120	relapse
T15	Condition 124 134	refractory
T17	Procedure 159 177	bone marrow sample
T18	Temporal 150 158	baseline
T19	Qualifier 189 215	Morphologically documented
T20	Qualifier 216 223	primary
T21	Condition 224 227	AML
T22	Condition 231 234	AML
T23	Condition 248 272	myelodysplastic syndrome
T24	Condition 274 277	MDS
T25	Value 283 287	≥20%
T26	Measurement 288 299	bone marrow
T27	Measurement 303 320	peripheral blasts
T29	Procedure 341 381	World Health Organization (WHO) criteria
T30	Procedure 396 412	pathology review
T31	Non-representable 442 480	Able to swallow the liquid study drug.
T32	Post-eligibility 442 480	Able to swallow the liquid study drug.
T33	Measurement 485 508	ECOG performance status
T34	Value 512 518	0 to 2
T35	Non-representable 520 972	7. In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor.
T36	Condition 1037 1047	toxicities
T37	Qualifier 1019 1036	non-hematological
T38	Qualifier 996 1018	clinically significant
T39	Temporal 1053 1058	prior
T40	Qualifier 1077 1085	≤Grade 1
T41	Value 1077 1085	≤Grade 1
T42	Qualifier 1048 1068	from prior treatment
T43	Procedure 1059 1068	treatment
T44	Drug 1110 1125	FLT3 inhibitors
T45	Mood 1129 1138	permitted
T46	Procedure 1097 1104	therapy
T47	Procedure 1156 1165	treatment
T48	Drug 1171 1176	AC220
T49	Negation 1140 1146	except
T50	Measurement 1183 1199	Serum creatinine
T51	Value 1200 1210	≤1.5 × ULN
T52	Measurement 1215 1247	glomerular filtration rate (GFR)
T53	Value 1248 1259	> 30 mL/min
T54	Measurement 1265 1280	Serum potassium
T55	Measurement 1265 1270;1282 1291	Serum magnesium
T56	Measurement 1265 1270;1297 1304	Serum calcium
T57	Value 1322 1365	at least within institutional normal limits
T59	Measurement 1372 1393	Total serum bilirubin
T60	Value 1394 1404	≤1.5 × ULN
T61	Measurement 1410 1444	Serum aspartate transaminase (AST)
T62	Measurement 1452 1478	alanine transaminase (ALT)
T63	Value 1479 1489	≤2.5 × ULN
T64	Measurement 1550 1564	pregnancy test
T65	Value 1541 1549	negative
T66	Procedure 1566 1577	urine β-hCG
T67	Person 1495 1502	Females
T68	Condition 1506 1528	childbearing potential
T70	Pregnancy_considerations 1585 1729	Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.
T71	Pregnancy_considerations 1495 1579	Females of childbearing potential must have a negative pregnancy test (urine β-hCG).
T72	Post-eligibility 1735 1777	Written informed consent must be provided.
